

REMARKS

The present invention relates to compositions and methods for internalization and degradation of urokinase-type plasminogen activator.

Claims 1-24 are pending in the present application. Claims 11-16 and 21-24 have been withdrawn from consideration as being drawn to a non-elected invention. Claim 1 has been canceled herein and claim 25 has been added herein. Therefore, upon entry of the instant Amendment, claims 2-4, 20 and 25 will be under consideration in this application.

Claims 2-4 have been amended herein to more particularly point out and distinctly claim the subject matter, which Applicants regard as their invention. Specifically, claims 2-4 have been amended per the Examiner's suggestion to render claims 2-4 independent. Further, claim 25 has been added to incorporate the subject matter of claim 3 into a pharmaceutical composition which is supported in the specification beginning on line 23 of page 18. Thus, no new matter has been added in any way.

Applicants are pleased to acknowledge that claim 20 has been deemed allowable in the present Office Action.

Rejection of claim 1 pursuant to 35 U.S.C. § 102(b)

The Examiner has maintained his rejection of claim 1 under 35 U.S.C. §102(b) as being anticipated by Pannekoek (International Publication No. WO 91/05048). Specifically, the Examiner is of the opinion that Pannekoek teaches the peptide sequence SGTVASSSTAVIVSARSAPEEIIMD. While not necessarily agreeing with the Examiner's rejection that claim 1 is anticipated, Applicants, in a good faith effort to expedite the prosecution of the instant application, have canceled claim 1 herein, thereby rendering this rejection moot.

Summary

Applicants are pleased to acknowledge that claim 20 has been deemed allowable in the present Office Action. Further, Applicants respectfully submit that each rejection and objection of the Examiner to the claims of the present application has been overcome or rendered moot, and that each of the claims 2-4, 20 and 25 is in condition for allowance. Such allowance is requested at the earliest possible date.

Respectfully submitted,

CINES ET AL.

November 17, 2003
(Date)

By:

Kathryn Doyle
KATHRYN DOYLE, Ph.D., J.D.
Registration No. 36,317
MORGAN, LEWIS & BOCKIUS, LLP
1701 Market Street
Philadelphia, PA 19103-2921
Telephone: (215) 963-5000
Direct Dial: (215) 963-4723
Facsimile: (215) 963-5001
E-Mail: kdoyle@morganlewis.com
Attorney for Applicants

KD/QDN

Jul